- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02017652
Validation of Fore-Sight Cerebral & Tissue Oximeter Saturation Measurements on Neonates ≤ 5 kg (FORE-SIGHT)
October 6, 2017 updated by: Anup Katheria, M.D., Sharp HealthCare
Validation of FORE-SIGHT Cerebral & Tissue Oximeter to Measure Cerebral & Somatic Tissue Oxygen Saturation Measurements at Different Body Locations on Neonates ≤ 5 kg
CASMED, INC. wishes to validate the next generation FORE-SIGHT-II (FS-II) NIRS tissue oximeter monitor for neonatal brain and somatic tissue oxygen saturation (StO2) measurements.
This monitor was recently FDA cleared for use on adult subjects.
Study Overview
Status
Completed
Conditions
Detailed Description
- Validate FS-II abdominal StO2 measurements from the intestines, liver, and flank to umbilical venous and arterial blood oxygen saturation.
- Validate FS-II cerebral StO2 measurements against the predicate FDA cleared FORE-SIGHT-I (FS-I) monitor.
- Collect data from FS-II sensors on the forehead and abdomen (intestine) for 24 hours to compare dynamic changes vs the pulse oximeter. For larger neonates, add a predicate FS-I sensor to the opposite side forehead for dynamic comparison to FS-II measurements.
- Obtain abdominal Near Infrared Spectroscopy (NIRS) data simultaneous with accepted measures of bowel motility (a. frequency and composition of stools, and b. Ultrasound assessment for the frequency and magnitude of bowel peristalsis, if available).
Study Type
Observational
Enrollment (Actual)
19
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92123
- Sharp Mary Birch Hospital for Women and Newborns
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 1 week (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Neonatal subjects (32 to 36 and 6/7 weeks), with umbilical venous catheterization will be enrolled from the NICU.
Demographic information of the subject will be recorded, including race, gender, weight, gestational age (GA), study age, and diagnosis.
Description
Inclusion Criteria:
Neonatal subjects (32 to 36 and 6/7 weeks), with umbilical venous catheterization will be enrolled from the Neonatal Intensive Care Unit.
Exclusion Criteria:
Enrollment in other studies during study period. Inability to tolerate ultrasounds or NIRS sensors
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Preterm Infants
Preterm infants 32 to 36 weeks will be eligible for this study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
StO2 measurement from intestines, liver and flank at time of venous and arterial blood oxygen saturation.
Time Frame: 1 hour
|
At or immediately following an umbilical venous blood draw for CO-oximetry, the FS-II NIRS Small sensor will be briefly placed on the abdominal wall for spot check measurements over the 1) left & 2) right flank, 3) liver and on three intestine locations: just inferior and lateral to the umbilicus in the 4) Right Lower Quadrant (RLQ) and 5) Left Lower Quadrant (LLQ) positions, as well as 6) Mid Lower Quadrant (MLQ).
Then a reference FS-I measurement of the 7) flank for 2 minutes will be done.
|
1 hour
|
Cerebral StO2 measurements from Fore-Sight FS-II monitor and Fore-Sight-I (FS-I) monitor.
Time Frame: 1 hour
|
Following abdominal measurements, the FS-II Small sensor will be placed on the head with the following positions in the following sequence 1) forehead, over the frontal cortex for two minutes; 2) the FS-II sensor is lifted off the head and placed back in the same forehead position to make a repeat measurement for two minutes; and 3) on the side of the head above the ear (frontal and parietal cortex) for two minutes.
For reference cerebral measurements, a FDA cleared FS-I Small sensor will be placed on the 4) forehead for two minutes; 5) the FS-I sensor will be removed and replaced on the same forehead position to make a repeat measurement for two minutes.
The sensors will take a measurement of 2 minutes in each position and 10 minutes total.
|
1 hour
|
Pulse and Tissue oxygen saturation and infant activity
Time Frame: 24 hours
|
Then two FS-II Small sensors will be attached longer term, one sensor on the forehead and one sensor on the abdomen (RLQ), with neonatal adhesives to allow monitoring for up to 24 hours.
Dynamic changes of StO2 at these locations will be observed, along with pulse oximetry SpO2 to capture any acute events such as apnea and bradycardia, which will help in modeling and verifying dynamic StO2 change behavior within the FS-II algorithm.
FS-II, and pulse oximetry data will be collected simultaneously on a laptop computer.
|
24 hours
|
Stool Interference Index over 24 hrs.
Time Frame: 24 hours
|
To calculate abdominal StO2 over the intestine regions, FORE-SIGHT also measures a stool interference index, which is used to compensate the algorithm to calculate StO2 correctly.
This stool interference index is hypothesized to be also useful as a bowel motility index based on its variability over time.
To test this hypothesis, the following two references for bowel motility will be tested: a) the study site will minimally record the number of stools for a period up to 24 hours.
The event field in the laptop computer will be used to note each observation.
b) if the study site has the capacity, abdominal ultrasound will be used to observe for the frequency and magnitude of bowel peristalsis.
These impressions will be added to an event field in the laptop computer.
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Anuup Katheria, MD, Sharp Mary Birch Hospital for Women & Newborns
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2013
Primary Completion (Actual)
December 1, 2014
Study Completion (Actual)
December 1, 2014
Study Registration Dates
First Submitted
December 11, 2013
First Submitted That Met QC Criteria
December 16, 2013
First Posted (Estimate)
December 23, 2013
Study Record Updates
Last Update Posted (Actual)
October 9, 2017
Last Update Submitted That Met QC Criteria
October 6, 2017
Last Verified
October 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- FORE-SIGHT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bowel Motility
-
Cairo UniversityCompletedEffect of Gum Chewing on Regaining Bowel Motility After Cesarean SectionEgypt
-
Asian Institute of Gastroenterology, IndiaRecruitingIrritable Bowel Syndrome | Small Bowel Disease | Motility DisorderIndia
-
Temple UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedGastroesophageal Reflux Disease | Functional Bowel DisordersUnited States
-
University of NottinghamCompletedOndansetron | Motility Disorder of Intestine | Small Bowel WaterUnited Kingdom
-
BayerCompletedFunctional and Motility Related Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional DyspepsiaGermany
-
University of Erlangen-Nürnberg Medical SchoolRecruitingGastrointestinal MotilityGermany
-
Armed Forces Hospitals, Southern Region, Saudi...Unknown
-
Xiyuan Hospital of China Academy of Chinese Medical...The First Affiliated Hospital of Henan University of Traditional Chinese... and other collaboratorsRecruitingNon-erosive Reflux Disease | Diarrhea-Predominant Irritable Bowel SyndromeChina
-
University of California, San FranciscoNot yet recruiting
-
University of California, San FranciscoRecruitingMotility FunctionUnited States